Newly Recognized CNS Tumors in the 2021 World Health Organization Classification: Imaging Overview with Histopathologic and Genetic Correlation

References

1. 1.↵
   1. Louis DN,
   2. Perry A,
   3. Wesseling P, et al

   . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23:1231–51 doi:10.1093/neuonc/noab106 pmid:34185076

   CrossRefPubMed
2. 2.↵
   1. Louis DN,
   2. Aldape K,
   3. Brat DJ, et al

   . cIMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy): a new initiative in advancing nervous system tumor classification. Brain Pathol 2017;27:851–52 doi:10.1111/bpa.12457 pmid:27997995

   CrossRefPubMed
3. 3.↵
   1. Louis DN,
   2. Wesseling P,
   3. Paulus W, et al

   . cIMPACT-NOW update 1: not otherwise specified (NOS) and not elsewhere classified (NEC). Acta Neuropathol 2018;135:481–84 doi:10.1007/s00401-018-1808-0 pmid:29372318

   CrossRefPubMed
4. 4.↵
   1. Louis DN,
   2. Giannini C,
   3. Capper D, et al

   . cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol 2018;135:639–42 doi:10.1007/s00401-018-1826-y pmid:29497819

   CrossRefPubMed
5. 5.↵
   1. Brat DJ,
   2. Aldape K,
   3. Colman H, et al

   . cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV.” Acta Neuropathol 2018;136:805–10 doi:10.1007/s00401-018-1913-0 pmid:30259105

   CrossRefPubMed
6. 6.↵
   1. Ellison DW,
   2. Hawkins C,
   3. Jones DT, et al

   . cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF(V600E) mutation. Acta Neuropathol 2019;137:683–87 doi:10.1007/s00401-019-01987-0 pmid:30848347

   CrossRefPubMed
7. 7.↵
   1. Brat DJ,
   2. Aldape K,
   3. Colman H, et al

   . cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol 2020;139:603–08 doi:10.1007/s00401-020-02127-9 pmid:31996992

   CrossRefPubMed
8. 8.↵
   1. Louis DN,
   2. Wesseling P,
   3. Aldape K, et al

   . cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol 2020;30:844–56 doi:10.1111/bpa.12832 pmid:32307792

   CrossRefPubMed
9. 9.↵
   1. Ellison DW,
   2. Aldape KD,
   3. Capper D, et al

   . cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors. Brain Pathol 2020;30:863–66 doi:10.1111/bpa.12866 pmid:32502305

   CrossRefPubMed
10. 10.↵
    1. Aboian MS,
    2. Solomon DA,
    3. Felton E, et al

    . Imaging characteristics of pediatric diffuse midline gliomas with histone H3 K27M mutation. AJNR Am J Neuroradiol 2017;38:795–800 doi:10.3174/ajnr.A5076 pmid:28183840

    Abstract/FREE Full Text
11. 11.↵
    1. Chen Y,
    2. Tian T,
    3. Guo X, et al

    . Polymorphous low-grade neuroepithelial tumor of the young: case report and review focus on the radiological features and genetic alterations. BMC Neurol 2020;20:123 doi:10.1186/s12883-020-01679-3 pmid:32252664

    CrossRefPubMed
12. 12.↵
    1. Bender K,
    2. Perez E,
    3. Chirica M, et al

    . High-grade astrocytoma with piloid features (HGAP): the Charite experience with a new central nervous system tumor entity. J Neurooncol 2021;153:109–20 doi:10.1007/s11060-021-03749-z pmid:33905054

    CrossRefPubMed
13. 13.↵
    1. Capper D,
    2. Jones DTW,
    3. Sill M, et al

    . DNA methylation-based classification of central nervous system tumours. Nature 2018;555:469–74 doi:10.1038/nature26000 pmid:29539639

    CrossRefPubMed
14. 14.↵
    1. Priesterbach-Ackley LP,
    2. Boldt HB,
    3. Petersen JK, et al

    . Brain tumour diagnostics using a DNA methylation-based classifier as a diagnostic support tool. Neuropathol Appl Neurobiol 2020;46:478–92 doi:10.1111/nan.12610 pmid:32072658

    CrossRefPubMed
15. 15.↵
    1. Osborn AG,
    2. Louis DN,
    3. Poussaint TY, et al

    . The 2021 World Health Organization Classification of Tumors of the Central Nervous System: what neuroradiologists need to know. AJNR Am J Neuroradiol 2022;43:928–37 doi:10.3174/ajnr.A7462 pmid:35710121

    Abstract/FREE Full Text
16. 16.↵
    1. Bale TA,
    2. Rosenblum MK

    . The 2021 WHO Classification of Tumors of the Central Nervous System: an update on pediatric low-grade gliomas and glioneuronal tumors. Brain Pathol 2022;32:e13060 doi:10.1111/bpa.13060 pmid:35218102

    CrossRefPubMed
17. 17.↵
    1. Chiang J,
    2. Harreld JH,
    3. Tinkle CL, et al

    . A single-center study of the clinicopathologic correlates of gliomas with a MYB or MYBL1 alteration. Acta Neuropathol 2019;138:1091–92 doi:10.1007/s00401-019-02081-1 pmid:31595312

    CrossRefPubMed
18. 18.↵
    1. Huse JT,
    2. Snuderl M,
    3. Jones DT, et al

    . Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway. Acta Neuropathol 2017;133:417–29 doi:10.1007/s00401-016-1639-9 pmid:27812792

    CrossRefPubMed
19. 19.↵
    1. Kurokawa M,
    2. Kurokawa R,
    3. Capizzano AA, et al

    . Neuroradiological features of the polymorphous low-grade neuroepithelial tumor of the young: five new cases with a systematic review of the literature. Neuroradiology 2022;64:1255–64 doi:10.1007/s00234-021-02879-5 pmid:35001164

    CrossRefPubMed
20. 20.↵
    1. Korshunov A,
    2. Capper D,
    3. Reuss D, et al

    . Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. Acta Neuropathol 2016;131:137–46 doi:10.1007/s00401-015-1493-1 pmid:26482474

    CrossRefPubMed
21. 21.↵
    1. Crowell C,
    2. Mata-Mbemba D,
    3. Bennett J, et al

    . Systematic review of diffuse hemispheric glioma, H3 G34-mutant: Outcomes and associated clinical factors. Neurooncol Adv 2022;4:vdac133 doi:10.1093/noajnl/vdac133 pmid:36105387

    CrossRefPubMed
22. 22.↵
    1. Picart T,
    2. Barritault M,
    3. Poncet D, et al

    . Characteristics of diffuse hemispheric gliomas, H3 G34-mutant in adults. Neurooncol Adv 2021;3:vdab061 doi:10.1093/noajnl/vdab061 pmid:34056608

    CrossRefPubMed
23. 23.↵
    1. Kurokawa R,
    2. Baba A,
    3. Kurokawa M, et al

    . Neuroimaging features of diffuse hemispheric glioma, H3 G34-mutant: a case series and systematic review. J Neuroimaging 2022;32:17–27 doi:10.1111/jon.12939 pmid:34632671

    CrossRefPubMed
24. 24.↵
    1. Korshunov A,
    2. Schrimpf D,
    3. Ryzhova M, et al

    . H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. Acta Neuropathol 2017;134:507–16 doi:10.1007/s00401-017-1710-1 pmid:28401334

    CrossRefPubMed
25. 25.↵
    1. Tauziede-Espariat A,
    2. Debily MA,
    3. Castel D, et al

    . An integrative radiological, histopathological and molecular analysis of pediatric pontine histone-wildtype glioma with MYCN amplification (HGG-MYCN). Acta Neuropathol Commun 2019;7:87 doi:10.1186/s40478-019-0738-y pmid:31177990

    CrossRefPubMed
26. 26.↵
    1. Tauziède-Espariat A,
    2. Debily MA,
    3. Castel D, et al

    . The pediatric supratentorial MYCN-amplified high-grade gliomas methylation class presents the same radiological, histopathological and molecular features as their pontine counterparts. Acta Neuropathol Commun 2020;8:104 doi:10.1186/s40478-020-00974-x pmid:32646492

    CrossRefPubMed
27. 27.↵
    1. Guerreiro Stucklin AS,
    2. Ryall S,
    3. Fukuoka K, et al

    . Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. Nat Commun 2019;10:4343 doi:10.1038/s41467-019-12187-5 pmid:31554817

    CrossRefPubMed
28. 28.↵
    1. Clarke M,
    2. Mackay A,
    3. Ismer B, et al

    . Infant high-grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes. Cancer Discov 2020;10:942–63 doi:10.1158/2159-8290.CD-19-1030 pmid:32238360

    Abstract/FREE Full Text
29. 29.↵
    1. Olsen TK,
    2. Panagopoulos I,
    3. Meling TR, et al

    . Fusion genes with ALK as recurrent partner in ependymoma-like gliomas: a new brain tumor entity? Neuro Oncol 2015;17:1365–73 doi:10.1093/neuonc/nov039 pmid:25795305

    CrossRefPubMed
30. 30.↵
    1. McNamara C,
    2. Mankad K,
    3. Thust S, et al

    . 2021 WHO classification of tumours of the central nervous system: a review for the neuroradiologist. Neuroradiology 2022;64:1919–50 doi:10.1007/s00234-022-03008-6 pmid:35869291

    CrossRefPubMed
31. 31.↵
    1. Fang Y,
    2. Wang YZ,
    3. Wei X, et al

    . Infant-type hemispheric glioma in a Chinese girl: a newly defined entity. Fetal Pediatr Pathol 2023;42:114–22 doi:10.1080/15513815.2022.2142488 pmid:35404193

    CrossRefPubMed
32. 32.↵
    1. Reinhardt A,
    2. Stichel D,
    3. Schrimpf D, et al

    . Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathol 2018;136:273–91 doi:10.1007/s00401-018-1837-8 pmid:29564591

    CrossRefPubMed
33. 33.↵
    1. Lucas CG,
    2. Sloan EA,
    3. Gupta R, et al

    . Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. Acta Neuropathol 2022;144:747–65 doi:10.1007/s00401-022-02478-5 pmid:35945463

    CrossRefPubMed
34. 34.↵
    1. Deng MY,
    2. Sill M,
    3. Sturm D, et al

    . Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters (DGONC): a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14. Neuropathol Appl Neurobiol 2020;46:422–30 doi:10.1111/nan.12590 pmid:31867747

    CrossRefPubMed
35. 35.↵
    1. Pickles JC,
    2. Mankad K,
    3. Aizpurua M, et al

    . A case series of diffuse glioneuronal tumours with oligodendroglioma-like features and nuclear clusters (DGONC). Neuropathol Appl Neurobiol 2021;47:464–67 doi:10.1111/nan.12680 pmid:33325069

    CrossRefPubMed
36. 36.↵
    1. Solomon DA,
    2. Korshunov A,
    3. Sill M, et al

    . Myxoid glioneuronal tumor of the septum pellucidum and lateral ventricle is defined by a recurrent PDGFRA p.K385 mutation and DNT-like methylation profile. Acta Neuropathol 2018;136:339–43 doi:10.1007/s00401-018-1883-2 pmid:30006677

    CrossRefPubMed
37. 37.↵
    1. Zamora C,
    2. Castillo M

    . From dysembryoplastic neuroepithelial tumors to myxoid glioneuronal tumors, a new entity. AJNR Am J Neuroradiol 2021;42:E77–78 doi:10.3174/ajnr.A7273 pmid:34531194

    FREE Full Text
38. 38.↵
    1. Lucas CG,
    2. Villanueva-Meyer JE,
    3. Whipple N, et al

    . Myxoid glioneuronal tumor, PDGFRA p.K385-mutant: clinical, radiologic, and histopathologic features. Brain Pathol 2020;30:479–94 doi:10.1111/bpa.12797 pmid:31609499

    CrossRefPubMed
39. 39.↵
    1. Narvaez EO,
    2. Inada BS,
    3. de Almeida P, et al

    . Myxoid glioneuronal tumour - report of three cases of a new tumour in a typical location and review of literature. BJR Case Rep 2021;7:20200139 doi:10.1259/bjrcr.20200139 pmid:35047190

    CrossRefPubMed
40. 40.↵
    1. Choi E,
    2. Kim SI,
    3. Won JK, et al

    . Clinicopathological and molecular analysis of multinodular and vacuolating neuronal tumors of the cerebrum. Hum Pathol 2019;86:203–12 doi:10.1016/j.humpath.2018.11.028 pmid:30550736

    CrossRefPubMed
41. 41.↵
    1. Nunes RH,
    2. Hsu CC,
    3. da Rocha AJ, et al

    . Multinodular and vacuolating neuronal tumor of the cerebrum: a new “Leave Me Alone” lesion with a characteristic imaging pattern. AJNR Am J Neuroradiol 2017;38:1899–904 doi:10.3174/ajnr.A5281 pmid:28705817

    Abstract/FREE Full Text
42. 42.↵
    1. Buffa GB,
    2. Chaves H,
    3. Serra MM, et al

    . Multinodular and vacuolating neuronal tumor of the cerebrum (MVNT): a case series and review of the literature. J Neuroradiol 2020;47:216–20 doi:10.1016/j.neurad.2019.05.010 pmid:31229580

    CrossRefPubMed
43. 43.↵
    1. Alizada O,
    2. Ayman T,
    3. Akgun MY, et al

    . Multinodular and vacuolating neuronal tumor of the cerebrum: Two cases and review of the literature. Clin Neurol Neurosurg 2020;197:106149 doi:10.1016/j.clineuro.2020.106149 pmid:32979644

    CrossRefPubMed
44. 44.↵
    1. Turan A,
    2. Tatar IG,
    3. Hekimoglu A, et al

    . Advanced magnetic resonance imaging findings of multinodular and vacuolating neuronal tumor. Turk Neurosurg 2021;31:725–30 doi:10.5137/1019-5149.JTN.32215-20.3 pmid:34169991

    CrossRefPubMed
45. 45.↵
    1. Pajtler KW,
    2. Witt H,
    3. Sill M, et al

    . Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 2015;27:728–43 doi:10.1016/j.ccell.2015.04.002 pmid:25965575

    CrossRefPubMed
46. 46.↵
    1. Sun S,
    2. Wang J,
    3. Zhu M, et al

    . Clinical, radiological, and histological features and treatment outcomes of supratentorial extraventricular ependymoma: 14 cases from a single center. J Neurosurg 2018;128:1396–402 doi:10.3171/2017.1.JNS161422 pmid:28686116

    CrossRefPubMed
47. 47.↵
    1. Wang J,
    2. Wang L,
    3. Fu L, et al

    . Supratentorial ependymoma with YAP1:FAM118B fusion: a case report. Neuropathology 2021;41:133–38 doi:10.1111/neup.12712 pmid:33480048

    CrossRefPubMed
48. 48.↵
    1. Wang X,
    2. Han F,
    3. Lv Y, et al

    . Supratentorial extraventricular ependymomas: imaging features and the added value of apparent diffusion coefficient. J Comput Assist Tomogr 2021;45:463–71 doi:10.1097/RCT.0000000000001164 pmid:34297516

    CrossRefPubMed
49. 49.↵
    1. Jabeen S,
    2. Konar SK,
    3. Prasad C, et al

    . Conventional and advanced magnetic resonance imaging features of supratentorial extraventricular ependymomas. J Comput Assist Tomogr 2020;44:692–98 doi:10.1097/RCT.0000000000001080 pmid:32842060

    CrossRefPubMed
50. 50.↵
    1. Mariet C,
    2. Castel D,
    3. Grill J, et al

    . Posterior fossa ependymoma H3 K27-mutant: an integrated radiological and histomolecular tumor analysis. Acta Neuropathol Commun 2022;10:137 doi:10.1186/s40478-022-01442-4 pmid:36104744

    CrossRefPubMed
51. 51.↵
    1. Pajtler KW,
    2. Wen J,
    3. Sill M, et al

    . Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. Acta Neuropathol 2018;136:211–26 doi:10.1007/s00401-018-1877-0 pmid:29909548

    CrossRefPubMed
52. 52.↵
    1. Sabin ND,
    2. Hwang SN,
    3. Klimo P Jr., et al

    . Anatomic neuroimaging characteristics of posterior fossa type a ependymoma subgroups. AJNR Am J Neuroradiol 2021;42:2245–50 doi:10.3174/ajnr.A7322 pmid:34674998

    Abstract/FREE Full Text
53. 53.↵
    1. Smith AB,
    2. Smirniotopoulos JG,
    3. Horkanyne-Szakaly I

    . From the radiologic pathology archives: intraventricular neoplasms: radiologic-pathologic correlation. Radiographics 2013;33:21–43 doi:10.1148/rg.331125192 pmid:23322825

    CrossRefPubMed
54. 54.↵
    1. Yonezawa U,
    2. Karlowee V,
    3. Amatya VJ, et al

    . Radiology profile as a potential instrument to differentiate between posterior fossa ependymoma (PF-EPN) group A and B. World Neurosurg 2020;140:e320–27 doi:10.1016/j.wneu.2020.05.063 pmid:32428725

    CrossRefPubMed
55. 55.↵
    1. Cavalli FMG,
    2. Hubner JM,
    3. Sharma T, et al

    . Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathol 2018;136:227–37 doi:10.1007/s00401-018-1888-x pmid:30019219

    CrossRefPubMed
56. 56.↵
    1. Raffeld M,
    2. Abdullaev Z,
    3. Pack SD, et al

    . High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma. Acta Neuropathol Commun 2020;8:101 doi:10.1186/s40478-020-00973-y pmid:32641156

    CrossRefPubMed
57. 57.↵
    1. Swanson AA,
    2. Raghunathan A,
    3. Jenkins RB, et al

    . Spinal cord ependymomas with MYCN amplification show aggressive clinical behavior. J Neuropathol Exp Neurol 2019;78:791–97 doi:10.1093/jnen/nlz064 pmid:31373367

    CrossRefPubMed
58. 58.↵
    1. Ghasemi DR,
    2. Sill M,
    3. Okonechnikov K, et al

    . MYCN amplification drives an aggressive form of spinal ependymoma. Acta Neuropathol 2019;138:1075–89 doi:10.1007/s00401-019-02056-2 pmid:31414211

    CrossRefPubMed
59. 59.↵
    1. Celano E,
    2. Salehani A,
    3. Malcolm JG, et al

    . Spinal cord ependymoma: a review of the literature and case series of ten patients. J Neurooncol 2016;128:377–86 doi:10.1007/s11060-016-2135-8 pmid:27154165

    CrossRefPubMed
60. 60.↵
    1. Koeller KK,
    2. Rosenblum RS,
    3. Morrison AL

    . Neoplasms of the spinal cord and filum terminale: radiologic-pathologic correlation. Radiographics 2000;20:1721–49 doi:10.1148/radiographics.20.6.g00nv151721 pmid:11112826

    CrossRefPubMedWeb of Science
61. 61.↵
    1. Hasselblatt M,
    2. Oyen F,
    3. Gesk S, et al

    . Cribriform neuroepithelial tumor (CRINET): a nonrhabdoid ventricular tumor with INI1 loss and relatively favorable prognosis. J Neuropathol Exp Neurol 2009;68:1249–55 doi:10.1097/NEN.0b013e3181c06a51 pmid:19915490

    CrossRefPubMed
62. 62.↵
    1. Tauziède-Espariat A,
    2. Guerrini-Rousseau L,
    3. Puget S, et al

    . A novel case of cribriform neuroepithelial tumor: a potential diagnostic pitfall in the ventricular system. Pediatr Blood Cancer 2021;68:e29037 doi:10.1002/pbc.29037 pmid:34151521

    CrossRefPubMed
63. 63.↵
    1. Arnold MA,
    2. Stallings-Archer K,
    3. Marlin E, et al

    . Cribriform neuroepithelial tumor arising in the lateral ventricle. Pediatr Dev Pathol 2013;16:301–07 doi:10.2350/12-12-1287-CR.1 pmid:23495723

    CrossRefPubMed
64. 64.↵
    1. Pawel BR

    . SMARCB1-deficient tumors of childhood: a practical guide. Pediatr Dev Pathol 2018;21:6–28 doi:10.1177/1093526617749671 pmid:29280680

    CrossRefPubMed
65. 65.↵
    1. Johann PD,
    2. Hovestadt V,
    3. Thomas C, et al

    . Cribriform neuroepithelial tumor: molecular characterization of a SMARCB1-deficient non-rhabdoid tumor with favorable long-term outcome. Brain Pathol 2017;27:411–18 doi:10.1111/bpa.12413 pmid:27380723

    CrossRefPubMed
66. 66.↵
    1. Ruland V,
    2. Hartung S,
    3. Kordes U, et al

    . Choroid plexus carcinomas are characterized by complex chromosomal alterations related to patient age and prognosis. Genes Chromosomes Cancer 2014;53:373–80 doi:10.1002/gcc.22148 pmid:24478045

    CrossRefPubMed
67. 67.↵
    1. Sturm D,
    2. Orr BA,
    3. Toprak UH, et al

    . New brain tumor entities emerge from molecular classification of CNS-PNETs. Cell 2016;164:1060–72 doi:10.1016/j.cell.2016.01.015 pmid:26919435

    CrossRefPubMed
68. 68.↵
    1. Li X,
    2. Wang W,
    3. Xi Y, et al

    . FOXR2 interacts with MYC to promote its transcriptional activities and tumorigenesis. Cell Rep 2016;16:487–97 doi:10.1016/j.celrep.2016.06.004 pmid:27346356

    CrossRefPubMed
69. 69.↵
    1. Tietze A,
    2. Mankad K,
    3. Lequin MH, et al

    . Imaging characteristics of CNS neuroblastoma-FOXR2: a retrospective and multi-institutional description of 25 cases. AJNR Am J Neuroradiol 2022;43:1476–80 doi:10.3174/ajnr.A7644

    Abstract/FREE Full Text
70. 70.↵
    1. Cardoen L,
    2. Tauziède-Espariat A,
    3. Dangouloff-Ros V, et al

    . Imaging features with histopathologic correlation of CNS high-grade neuroepithelial tumors with a BCOR internal tandem duplication. AJNR Am J Neuroradiol 2022;43:151–56 doi:10.3174/ajnr.A7367 pmid:34887247

    Abstract/FREE Full Text
71. 71.↵
    1. Matsumura N,
    2. Goda N,
    3. Yashige K, et al

    . Desmoplastic myxoid tumor, SMARCB1-mutant: a new variant of SMARCB1-deficient tumor of the central nervous system preferentially arising in the pineal region. Virchows Arch 2021;479:835–39 doi:10.1007/s00428-020-02978-3 pmid:33420834

    CrossRefPubMed
72. 72.↵
    1. Thomas C,
    2. Wefers A,
    3. Bens S, et al

    . Desmoplastic myxoid tumor, SMARCB1-mutant: clinical, histopathological and molecular characterization of a pineal region tumor encountered in adolescents and adults. Acta Neuropathol 2020;139:277–86 doi:10.1007/s00401-019-02094-w pmid:31732806

    CrossRefPubMed
73. 73.↵
    1. Wang YE,
    2. Chen JJ,
    3. Wang W, et al

    . A case of desmoplastic myxoid tumor, SMARCB1 mutant, in the pineal region. Neuropathology 2021;41:37–41 doi:10.1111/neup.12695 pmid:32901946

    CrossRefPubMed
74. 74.↵
    1. Sloan EA,
    2. Chiang J,
    3. Villanueva-Meyer JE, et al

    . Intracranial mesenchymal tumor with FET-CREB fusion-A unifying diagnosis for the spectrum of intracranial myxoid mesenchymal tumors and angiomatoid fibrous histiocytoma-like neoplasms. Brain Pathol 2021;31:e12918 doi:10.1111/bpa.12918 pmid:33141488

    CrossRefPubMed
75. 75.↵
    1. Sbaraglia M,
    2. Righi A,
    3. Gambarotti M, et al

    . Ewing sarcoma and Ewing-like tumors. Virchows Arch 2020;476:109–19 doi:10.1007/s00428-019-02720-8 pmid:31802230

    CrossRefPubMed
76. 76.↵
    1. Kallen ME,
    2. Hornick JL

    . The 2020 WHO Classification: what’s new in soft tissue tumor pathology? Am J Surg Pathol 2021;45:e1–e23 doi:10.1097/PAS.0000000000001552 pmid:32796172

    CrossRefPubMed
77. 77.↵
    1. Yoshida A,
    2. Goto K,
    3. Kodaira M, et al

    . CIC-rearranged sarcomas: a study of 20 cases and comparisons with Ewing sarcomas. Am J Surg Pathol 2016;40:313–23 doi:10.1097/PAS.0000000000000570 pmid:26685084

    CrossRefPubMed
78. 78.↵
    1. Le Loarer F,
    2. Pissaloux D,
    3. Watson S, et al

    . Clinicopathologic features of CIC-NUTM1 sarcomas, a new molecular variant of the family of CIC-fused sarcomas. Am J Surg Pathol 2019;43:268–76 doi:10.1097/PAS.0000000000001187 pmid:30407212

    CrossRefPubMed
79. 79.↵
    1. Donahue JE,
    2. Yakirevich E,
    3. Zhong S, et al

    . Primary spinal epidural CIC-DUX4 undifferentiated sarcoma in a child. Pediatr Dev Pathol 2018;21:411–17 doi:10.1177/1093526617707856 pmid:28474974

    CrossRefPubMed
80. 80.↵
    1. Song K,
    2. Huang Y,
    3. Xia CD, et al

    . A case of CIC-rearranged sarcoma with CIC-LEUTX gene fusion in spinal cord. Neuropathology 2022;42:555–62 doi:10.1111/neup.12850 pmid:35859319

    CrossRefPubMed
81. 81.↵
    1. Hu W,
    2. Wang J,
    3. Yuan L, et al

    . Case report: a unique case of pediatric central nervous system embryonal tumor harboring the CIC-LEUTX fusion, germline NBN variant and somatic TSC2 mutation: expanding the spectrum of CIC-rearranged neoplasia. Front Oncol 2020;10:598970 doi:10.3389/fonc.2020.598970 pmid:33344249

    CrossRefPubMed
82. 82.↵
    1. Kamihara J,
    2. Paulson V,
    3. Breen MA, et al

    . DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor. Mod Pathol 2020;33:1910–21 doi:10.1038/s41379-020-0516-1 pmid:32291395

    CrossRefPubMed
83. 83.↵
    1. Lee JC,
    2. Villanueva-Meyer JE,
    3. Ferris SP, et al

    . Primary intracranial sarcomas with DICER1 mutation often contain prominent eosinophilic cytoplasmic globules and can occur in the setting of neurofibromatosis type 1. Acta Neuropathol 2019;137:521–25 doi:10.1007/s00401-019-01960-x pmid:30649606

    CrossRefPubMed
84. 84.↵
    1. Diaz Coronado RY,
    2. Mynarek M,
    3. Koelsche C, et al

    . Primary central nervous system sarcoma with DICER1 mutation-treatment results of a novel molecular entity in pediatric Peruvian patients. Cancer 2022;128:697–707 doi:10.1002/cncr.33977 pmid:34674226

    CrossRefPubMed
85. 85.↵
    1. de Kock L,
    2. Priest JR,
    3. Foulkes WD, et al

    . An update on the central nervous system manifestations of DICER1 syndrome. Acta Neuropathol 2020;139:689–701 doi:10.1007/s00401-019-01997-y pmid:30953130

    CrossRefPubMed
86. 86.↵
    1. Leelatian N,
    2. Goss J,
    3. Pastakia D, et al

    . Primary intracranial sarcoma, DICER1-mutant presenting as a pineal region tumor mimicking pineoblastoma: case report and review of the literature. J Neuropathol Exp Neurol 2022;81:762–64 doi:10.1093/jnen/nlac053 pmid:35789272

    CrossRefPubMed
87. 87.↵
    1. Rashidi A,
    2. Luna LP,
    3. Rodriguez F, et al

    . Teaching NeuroImages: intracranial DICER1-associated spindle cell sarcoma in a child. Neurology 2020;95:e2176–77 doi:10.1212/WNL.0000000000010374 pmid:32680948

    CrossRefPubMed
88. 88.↵
    1. Shih RY,
    2. Schroeder JW,
    3. Koeller KK

    . Primary tumors of the pituitary gland: radiologic-pathologic correlation. Radiographics 2021;41:2029–46 doi:10.1148/rg.2021200203 pmid:34597177

    CrossRefPubMed
89. 89.↵
    1. Chhuon Y,
    2. Weon YC,
    3. Park G, et al

    . Pituitary blastoma in a 19-year-old woman: a case report and review of literature. World Neurosurg 2020;139:310–13 doi:10.1016/j.wneu.2020.04.096 pmid:32339726

    CrossRefPubMed
90. 90.↵
    1. Liu AP,
    2. Kelsey MM,
    3. Sabbaghian N, et al

    . Clinical outcomes and complications of pituitary blastoma. J Clin Endocrinol Metab 2021;106:351–63 doi:10.1210/clinem/dgaa857 pmid:33236116

    CrossRefPubMed